Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) and CERo Therapeutics (NASDAQ:CERO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Volatility & Risk
Jupiter Neurosciences has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Jupiter Neurosciences and CERo Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
| CERo Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Valuation & Earnings
This table compares Jupiter Neurosciences and CERo Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jupiter Neurosciences | $40,448.00 | 213.48 | -$8.65 million | ($0.27) | -0.88 |
| CERo Therapeutics | N/A | N/A | -$8.30 million | ($71.01) | 0.00 |
CERo Therapeutics has lower revenue, but higher earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
29.6% of CERo Therapeutics shares are held by institutional investors. 50.8% of Jupiter Neurosciences shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Jupiter Neurosciences and CERo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jupiter Neurosciences | N/A | -1,314.62% | -228.63% |
| CERo Therapeutics | N/A | N/A | -209.40% |
Summary
CERo Therapeutics beats Jupiter Neurosciences on 7 of the 11 factors compared between the two stocks.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
